Lululemon (LULU) Q1 2026 Earnings Call June 05, 2025 04:30 PM ET Speaker0 Thank you for standing by. This is the conference operator. Welcome to the Lululemon Athletica Inc. First Quarter twenty twenty five Financial Results Conference Call. As a reminder, all participants are in listen only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. I would now like to turn the conference over to Howard Tuban, Vice President, Investor Relations for Lulu ...

Financial Data and Key Metrics Changes - The company ended Q1 2025 with 147,157 active subscribers, up approximately 1% year over year, and the highest number of ending subscribers in company history [31] - Total revenue for Q1 2025 was $69.6 million, down $5.4 million or 7.2% year over year [31] - Gross margins decreased to 31.5% in Q1 2025 from 37.9% in Q1 2024, reflecting higher revenue share costs and fulfillment costs [33] - Adjusted EBITDA for Q1 2025 was negative $1.3 million, compared to positive $6.5 million in Q1 2024 [34] - Free cash flow for Q1 2025 was negative $6.4 million, a decrease from negative $1.4 million in Q1 2024 [35] Business Line Data and Key Metrics Changes - Subscription and reserve rental revenue decreased by 6.2% year over year in Q1 2025, primarily due to lower average revenue per subscriber [32] - Fulfillment costs were $20.4 million in Q1 2025, slightly down from $20.6 million in Q1 2024 [32] - The company launched 36 new brands and over 1,000 new styles, resulting in a 24% year-over-year increase in inventory volume received [8][9] Market Data and Key Metrics Changes - The company reported a 23% higher share of views, 46% more hearts, and a 14% higher love rate for its spring 2025 inventory compared to the previous year [9] - April add-on gross bookings increased by 11% year over year, indicating higher customer engagement [9] Company Strategy and Development Direction - The company is focused on a transformation strategy that includes increasing inventory breadth and depth, innovating products, and enhancing customer service [4][5] - Plans for Q2 2025 include launching over 40 new brands and posting over 2,700 new styles [12] - The company aims to improve customer retention through personalized services and a new rewards program [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the effectiveness of their inventory and product strategies, noting the strongest quarterly customer retention in four years [23] - The company anticipates continued improvement in subscriber growth and retention throughout fiscal year 2025 [30] - Management acknowledged the uncertain environment but emphasized the value of renting over buying for consumers [38] Other Important Information - The company has shifted its marketing strategy towards transparency and community engagement, resulting in a 163% increase in social media engagement [21] - The company is planning to scale customer service initiatives, including a concierge service for new and rejoining customers [16][18] Q&A Session Summary Question: Why has it taken until fiscal year 2025 to implement these strategies? - Management explained that previous focus was on managing cash consumption and reducing costs, which limited inventory purchases until now [26][28] Question: What are the expectations for subscriber growth and revenue? - Management expects double-digit growth in ending active subscribers for fiscal year 2025, with revenue growth lagging behind due to higher promotional spending [36][30] Question: How does the company plan to handle potential tariff impacts? - Management stated that their guidance does not factor in potential tariff impacts, as they have already placed orders for most inventory receipts for fiscal year 2025 [37]

Financial Data and Key Metrics Changes - Braze reported Q1 2026 revenue of $162.1 million, representing a nearly 20% year-over-year increase [6][18] - Non-GAAP operating margin improved by over 900 basis points year-over-year, with non-GAAP net income of $7 million and free cash flow of nearly $23 million [6][24] - Total remaining performance obligation (RPO) was $829.3 million, up 26% year-over-year, while current RPO increased by 24% year-over-year to $522 million [20] Business Line Data and Key Metrics Changes - Subscription revenue accounted for 96% of total revenue, with the remaining 4% from professional services and onboarding fees [18] - The customer count rose to 2,342, an increase of 11% year-over-year, with large customers (spending at least $500,000 annually) growing by 24% year-over-year to 262 [18][19] - Dollar-based net retention (DBNR) was 109 overall and 112 for large customers, indicating strong customer expansion [19] Market Data and Key Metrics Changes - Revenue outside the U.S. contributed 46% of total revenue, up from 45% in the previous quarter [20] - The company secured new business wins across various sectors, including fintech, luxury retail, and healthcare, demonstrating broad market strength [7][9] Company Strategy and Development Direction - Braze aims to become the leading customer engagement platform globally, focusing on AI-driven solutions and first-party data utilization [6][10] - The acquisition of OfferFit is expected to enhance Braze's AI capabilities and customer engagement strategies, allowing for more personalized experiences [12][14] - The company is committed to investing in technology and community to elevate customer engagement practices [11] Management's Comments on Operating Environment and Future Outlook - Management noted that global trade concerns have not significantly impacted deal cycles, and they expect continued momentum despite a noisy macro environment [6][7] - The company anticipates that the legacy replacement cycle and vendor consolidation trends will persist, providing opportunities for market share growth [9][10] - Management expressed confidence in achieving sustained profitable growth while navigating economic uncertainties [6][27] Other Important Information - Braze's non-GAAP gross profit for the quarter was $112 million, with a gross margin of 69.3%, up from 67.9% in the prior year [21] - The company ended the quarter with approximately $540 million in cash and equivalents, indicating strong liquidity [24] Q&A Session Summary Question: Reconciling sequential growth and CRPO dynamics - Management acknowledged that CRPO is sensitive to renewal dollars and emphasized that revenue is the key metric to watch for macro stabilization [32][34] Question: Performance of Project Catalyst - Project Catalyst is in private beta, and while specific uplift case studies are not available, initial results show promise in optimizing customer engagement strategies [43][45] Question: Renewal cadence and OfferFit feedback - Q1 was a heavy renewal quarter, with expectations for a drop in Q2 and Q3, followed by another increase in Q4 [63] - Early feedback on OfferFit has been positive, with strong interest from customers and successful presentations at events [55][57] Question: Pricing and packaging changes - The new pricing model has relaxed data point limits, improving customer flexibility and reducing friction in sales cycles [70][72] Question: Impact of OfferFit on EBIT guidance - OfferFit is expected to contribute significantly to EBIT, with around 80% of the impact attributed to its integration [74][76]

Petco Health and Wellness Company (WOOF) Q1 2026 Earnings Call June 05, 2025 04:30 PM ET Speaker0 afternoon, and welcome to the Petco First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Tina Romani, Head of Investor Relations and Treasury. Please go ahead. Speaker1 Good afternoon, and t ...

Torrid (CURV) Q1 2026 Earnings Call June 05, 2025 04:30 PM ET Speaker0 Greetings and welcome to the Torrid Holdings Inc. First Quarter Fiscal twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jemweh Abeleu, Chief Accounting Officer and Senior Vice President. Thank you, and you may begin. Speaker ...

Summary of Roivant Sciences (ROIV) Conference Call Company Overview - Roivant Sciences is a clinical stage biopharma company focused on developing valuable medicines with a portfolio of late-stage programs [4][5] - The company has approximately $5 billion in cash, primarily from a previous transaction involving an anti T1 antibody [6] Key Programs and Pipeline - **Anti FcRn Franchise**: Developed through subsidiary Immunovant, focusing on indications like Graves' disease and myasthenia gravis (MG) [5][59] - **JAK1/TYK2 Inhibitor**: Targeting dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis [5] - **PHLD Program**: Known as Mosley Siguat, with significant data expected in the near future [5] - Upcoming phase three readout for dermatomyositis expected in the second half of the year, which could lead to a commercial launch [7][24] Market Opportunities - The dermatomyositis market is estimated to have around 40,000 to 70,000 patients, with the potential for Roivant to be the first oral novel medication in this space [27][28] - The company anticipates a significant commercial opportunity, with pricing expected to be competitive with existing therapies like IVIG [52][51] Business Development (BD) Strategy - The current biotech market presents opportunities for Roivant as valuations decrease and expectations shift [11][12] - The company is exploring indication expansions organically, particularly in the FcRn and JAK1/TYK2 areas [13][14] - Roivant is open to various therapeutic areas, including immunology, respiratory, and rare diseases, while being cautious about competitive dynamics in oncology and gene therapy [20] Regulatory and Clinical Considerations - The company is focused on achieving orphan drug designation for its dermatomyositis treatment, which provides benefits in user fees and FDA engagement [41][42] - The primary endpoint for the phase three trial is a statistically significant improvement in the Total Improvement Score (TIS) [30][40] - Placebo effects are a concern, but the company is implementing strategies to mitigate these risks, including a mandatory steroid taper in the trial protocol [34][39] Immunovant and Future Prospects - Immunovant's lead drug, IMG1402, is in pivotal trials for multiple indications, with promising data supporting deeper IgG suppression leading to better clinical outcomes [59][60] - The company aims to redefine success metrics in MG, moving towards deeper clinical responses rather than just baseline improvements [63][65] - Roivant holds a 58% stake in Immunovant and is optimistic about the potential for multiple blockbuster indications [72][74] Legal Matters - Roivant is involved in patent litigation against Pfizer and Moderna regarding their COVID-19 vaccines, with expectations for a trial in the near future [76][77] Conclusion - Roivant Sciences is positioned for significant growth with a robust pipeline and strategic focus on valuable therapeutic areas, while navigating challenges in the current biotech landscape and legal environment [4][11][76]

Aldeyra Therapeutics (ALDX) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference. My name is Clara Dunn, one of the biotech analysts here at Jefferies. So it's my pleasure here to help Aldara's CEO, Doctor. Todd Brady, here with us today for this fireside chat. Welcome. Speaker1 Thank you, Clara. Speaker0 So before we dig into details of your pipeline, maybe it will be helpful for you to give us a quick overview of the company and wha ...

EDAP TMS (EDAP) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Okay. Alright. Good afternoon. My name is Michael Sarcone. I'm an analyst on the US Medical Supplies and Devices team, this is day two of the Jefferies twenty twenty five New York Healthcare Conference. This is a session with EDAP Focal One. And with us from the company, we've got Ryan Rhodes, CEO Ken Moback, CFO and John Francis who heads the IR function. Ryan Rhodes is going to give a presentation, some prepared commentary and then we'll o ...

Replimune Group (REPL) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Well, these guys in the back, they turn it on for you. Okay. The middle, please. Speaker1 I was gonna take this one. Speaker2 This is Speaker1 on a mic. Speaker0 This Okay. Speaker1 You can take a wee bit. Speaker0 Would you like to be in the middle? Nope. K. Speaker2 Rose between two thorns. K. Well said. Alright. Okay. Alright. Welcome everyone to Jefferies twenty twenty five Healthcare Global Conference. My name is Roger Song, one ...

Hyperfine (HYPR) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Alright. We're kicking off the next session here. My name is Young Lee, one of the med tech analysts at Jefferies, and pleased to be joined by Hyperfine. From the company, we have the CEO to my right, Maria Sainz. I guess I'll just pass the floor off to you for the presentation. Thank you. Speaker1 Thank you, and thank you for, inviting me. I'm very excited to be here. Here are our disclosures. I'm actually very excited to be here today. Hy ...